KYIV, Nov 25 – Biopharmaceutical company Biopharma has collected enough plasma for the production of the first batch of hyperimmune immunoglobulin, a drug to treat COVID-19, Kostiantyn Yefymenko, Biopharma president, said.

The lack of plasma collected from recovered COVID-19 patients has been earlier cited by the company as the main reason why Biopharma had been delaying production of COVID-19 treatment drug.